Editorial Staff

Study: Growth of Antibiotic-Resistant Infections Could Have Massive Human, Financial Costs

/in , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Dysfunctional market, perverse incentives caused by Medicare reimbursement rates contribute to problem

BOSTON – The world was blindsided by COVID-19, but a new Pioneer Institute study finds that even as we continue to wrestle with the pandemic, another threat looms that scientists have long known about but the nation has thus far failed to address: the growth of antibiotic-resistant infections.

“Market dysfunction and perverse Medicare reimbursement rates have led to a growth in infections that resist antibiotics,” said Gunnar Esiason, author of “Antimicrobial Resistance: Learning from the current global health crisis to prevent another one.”  If we don’t solve this problem, the human and economic costs are likely to be astronomical.”

In the U.S., around two million people per year contract infections that are resistant to antibiotics and as many as 23,000 of them die.  These drug-resistant infections account for $20 billion in health care costs.

If unchecked, it’s forecast that the problem could claim 10 million lives per year worldwide and be responsible for the loss of $100 trillion in economic output by 2050.

Antibiotic resistance is driven by years of overuse and misuse of antibiotics.  Medicare is the nation’s largest payer, and its recipients account for the majority of resistant infections.  Because hospitals receive the same reimbursement whether they use an older generic drug or a new drug that is likely to be more expensive, there is a financial incentive to prescribe the older drugs, even if those drugs may not be as effective because patients have built up resistance to them.

The continuing use of older drugs exacerbates the antibiotic resistance problem.  It can also result in higher health care costs because additional treatments are required to treat the infection, or cause hospitals to use unnecessarily strong antibiotics to treat it effectively.

Hospitals favoring older generic drugs even if they are less effective makes it harder for new drugs to recoup development costs, which can be up to $2.6 billion.  As a result, investment is down and the number of new antibiotics approved by the FDA has fallen in recent years.  In addition, companies working on new antibiotics are more likely to be small firms or start-ups that are less financially stable.

With its large concentration of life science companies, Massachusetts could be particularly hard hit if investment in new antibiotics continues to lag.

One effort to address the antibiotic-resistant infection problem is the DISARM Act, which was introduced in Congress last year.  The legislation would increase Medicare antibiotic reimbursements and eliminate the incentive to prescribe less expensive drugs that are often less effective by allowing for the reimbursement of all antibiotics, regardless of cost.  Backers argue that the bill would slow the growth of resistant infections by ending the overuse of older drugs that have become less effective, and that newer, more effective antibiotics could reduce long-term costs.

Esiason also recommends mounting a broad awareness campaign that would tie this impending public health and economic threat to our current battle against COVID-19.

About the Author

Gunnar Esiason is a cystic fibrosis and rare disease patient leader, who is passionate about early stage drug development, patient empowerment and health policy. He is a second-year M.B.A. student at the Tuck School of Business at Dartmouth and is also working towards a Master of Public Health degree at the Dartmouth Institute for Health Policy and Clinical Practice. At Tuck, Gunnar serves as a Tuck Center for Health Care MBA Fellow, a health care club co-chair and a club hockey captain. Prior to Tuck, Gunnar received a BA form Boston College in 2013, worked on an enteral feeding product at a medical nutrition company, was appointed to the board of directors at the Boomer Esiason Foundation, and was the head coach of his high school alma mater’s varsity hockey team. Gunnar maintains the roles of patient advocate and director of patient outreach at the Boom­er Esiason Foundation.

He has consulted on clinical trial development, a real-world evidence population health study, and a cystic fibrosis-specific mental health and wellness screening tool. In 2019, Gunnar delivered the pre-commencement address at the St. Louis Uni­versity School of Medicine commencement exercises. He has also been featured as a keynote speaker at more than two-doz­en top medical centers, biotech conferences, and health indus­try events across the United States. His health policy opinions have been featured in Newsweek, The New York Daily News, The Hill, US News & World Report, and Morning Consult.

About Pioneer

Mission: Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachu­setts and beyond.

Vision: Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values: Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibili­ty, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Updates On Our Life Sciences Work!

Related Posts

Why the jump in non-COVID deaths?

The Wall Street Journal echoes our warning about the rise of non-COVID-related deaths.

Olympic-Scale Doctor Shortage: Tapping International Talent

Host Joe Selvaggi talks with Pioneer Institute's Senior Healthcare Policy Fellow Josh Archambault about the shortage of doctors in the U.S. and the potential for licensing reform to attract medical expertise from around the world to reduce future healthcare shortages and provide incentives for immigrating professionals to work in underserved communities.

Testimony in opposition to S. 2651 to impose price controls

Testimony submitted on February 4, 2022 in opposition to S. 2651, legislation that would impose price controls on one of Massachusetts most important economic sectors, biopharmaceuticals.

How did COVID impact Massachusetts’ long-term care facilities?

Pioneer Institute has filed a Public Records Act request related to COVID's impact on Massachusetts’ long-term care facilities because the Institute believes this is a matter of obvious importance, both on principle (the public has a right to know the facts), and for purposes of evaluating – and where possible improving – public policy. 

Massachusetts Telehealth Report Card: Are We Embracing Disruption for Better Quality of Care?

Hubwonk host Joe Selvaggi talks with Pioneer Senior Fellow in Healthcare Josh Archambault about his newest research paper, produced with the Cicero Institute and the Reason Foundation, on states' success in implementing telehealth to improve healthcare outcomes. They discuss how Massachusetts has used remote medicine to better reach patients and serve their needs.

Am I Contagious? Divining Covid’s Community Conundrum

Hubwonk host Joe Selvaggi talks with Alva10 CEO and precision medicine expert Hannah Mamuszka about which tests are best for determining who is contagious and the implications for the CDC’s new isolation recommendations.

Face Masks Lifted: Scientists Weigh In With Comprehensive Efficacy Studies

Hubwonk host Joe Selvaggi talks with Harvard Medical School professor, Dr. Jonathan Darrow, about the observations of his recent paper, Evidence for Community Cloth Face Masking to Limit the Spread of SARS-CoV-2: A Critical Review, in which he examines the range, quality, and scientific observations of mask wearing efficacy studies.

Building Healthcare Bigger: New Bill Is Good Medicine or Ill-Designed Cost Shift

This week on Hubwonk, host Joe Selvaggi talks with Josh Archambault, Pioneer Institute’s Senior Fellow in Healthcare, about the healthcare provisions in the pending Build Back Better Act and their likely impact on the coverage and cost to Americans in the wake of Covid-19.

The Promise and Challenges of Rare Cancer Treatments

Dr. William Smith, Pioneer Institute's Visiting Fellow in Life Sciences, spoke about the challenges and opportunities for rare cancer treatments, in a video interview produced by Rare Cancers, a patient group based in Australia, for the November 26th CAN Forum. 

COVID’s Unintended Victims: Traditional Diseases Overlooked at the Public’s Peril

This week on Hubwonk, host Joe Selvaggi talks with Pioneer Institute’s Visiting Fellow in Life Sciences, Dr. Bill Smith, about his newest research paper, “An “Impending Tsunami” in Mortality from Traditional Diseases,” which sounds the alarm that the public health community’s focus on COVID-19 has caused many to avoid seeking medical attention for other illnesses. As a result, more Americans are dying from fear of COVID than from the disease itself.

Vaccine Development Renaissance: Pandemic Brings Niche Industry into Mainstream

This week on Hubwonk, host Joe Selvaggi talks with virologist, Dr. Peter Kolchinsky, about the explosion of vaccine technologies and innovations brought into the spotlight by the massive investment to fight the pandemic, and dives deeply into the exciting promise of vaccines to combat an ever-widening range of disease.

Shifting COVID-19 Goalposts: Moving from Zero Infections to Zero Deaths

This week on Hubwonk, host Joe Selvaggi talks with surgeon and author Dr. Marty Makary about the power and durability of vaccines, natural immunity and clinical therapies, that are overshadowed by the public health community's continued target of zero COVID-19 infections.
A Woman Helping a Disabled Man in a Wheelchair

An Act advancing health care research and decision-making centered on patients and people with disabilities

On November 9th, 2021, William Smith, Pioneer Institute Visiting Fellow in Life Sciences, submitted the following testimony to the Massachusetts Legislature in support of House Bill 201, which addresses a number of flaws and infirmities in the Quality Adjusted Life Years (QALYs) methodology that is utilized by a number of foreign nations in evaluating the value of medicines.

An “Impending Tsunami” in Mortality from Traditional Diseases?

This report examines whether, after the COVID-19 pandemic subsides, the U.S. will have another looming public health crisis emerging from patients failing to have had their cardiology needs addressed properly during the lockdowns. Moreover, if we surmise that a follow-on public health crisis will emerge, we can also conclude that certain population segments are going to be more impacted by CVD, as there are documented health disparities in this therapeutic area. Finally, there are policy changes that could be taken to mitigate a possible spike in CVD adverse events; the paper will close by recommending certain policy changes.

Study: Decline in Cardiovascular Health Screenings During COVID-19 Pandemic Poses New Public Health Threat

Pioneer Institute today released a new analysis focused on cardiovascular disease, An “Impending Tsunami” in Mortality from Traditional Diseases?, that examines how the COVID-19 pandemic has created another unrelated public health crisis. The Pioneer analysis examines how a single-minded public health focus on COVID-19, social distancing, and lockdowns drove reductions in screenings, diagnoses, and early treatment for complex conditions such as heart disease.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Untangling Variants & Outbreaks: Can Vaccines & Natural Immunity Outrun Delta?

Hubwonk host Joe Selvaggi talks with author, surgeon, and public health expert Dr. Marty Makary about the COVID-19 Delta Variant, the durability of natural and vaccinated immunity, the benefits of booster shots, and the health risks for children as we move into the fall.

Targeting Pharma: Infrastructure Bill Employs Price Controls To Offset Unprecedented Price Tag

Hubwonk host Joe Selvaggi talks with Pioneer Institute Visiting Fellow in Life Sciences Dr. William Smith about how the price control features of the emerging $3.5 trillion infrastructure bill might affect the pharmaceutical Industry, both nationwide and here in Massachusetts, and what effect that change will have on drug consumers.